

Wes Moore, Governor · Aruna Miller, Lt. Governor · Laura Herrera Scott, M.D., M.P.H., Secretary

February 6, 2025

The Honorable Pamela Beidle Chair, Senate Finance Committee 3 East Miller Office Building Annapolis, MD 21401-1991

RE: Senate Bill (SB) 459 – Education and Health - Emergency Use Epinephrine -Alterations – Letter of Support

Dear Chair Beidle and Committee Members:

The Maryland Department of Health (the Department) respectfully submits this letter of support for Senate Bill 459 – Education and Health - Emergency Use Epinephrine - Alterations. This bill alters all references to "auto-injectable epinephrine" to "emergency use epinephrine" in statutes that impact school health, youth camps, child care, institutions of higher education, and naturopaths, and provides a definition for "emergency use epinephrine."

The authorization for trained school staff to administer stock epinephrine to students experiencing anaphylaxis is a critical emergency measure when a student does not have access to their own prescribed epinephrine. In the 2023-24 school year, Maryland public schools reported 32,000 students with life-threatening allergies/anaphylaxis who could potentially require administration of stock epinephrine. Within that same year, it was reported that stock auto-injectable epinephrine—the only form allowable by law—was administered 69 times.

The Department supports altering the term "auto-injectable epinephrine" to "emergency use epinephrine" as defined in SB 459. This legislative change will allow school staff to stock and administer alternative epinephrine delivery systems for use in an emergency. Auto-injectable epinephrine requires a needle for medication delivery, and fear of needles is one of the factors associated with underuse of this potentially life-saving medication.¹ The use of FDA-approved non-needle epinephrine delivery systems such as intranasal epinephrine has the potential to increase student and school staff comfort with emergency epinephrine administration, which could be life-saving for students experiencing anaphylaxis.

If you would like to discuss this further, please do not hesitate to contact Sarah Case-Herron, Director of Governmental Affairs at <u>sarah.case-herron@maryland.gov</u>.

¹ Lieberman, J. et al. (2023). Innovations in the treatment of anaphylaxis: A review of recent data. *Annals of Allergy, Asthma & Immunology* 131(2), 185-193. <u>https://doi.org/10.1016/j.anai.2023.05.033</u>

Sincerely,

Laura Herrera Scott, M.D., M.P.H. Secretary